BioNTech and iBio Compared on Financial Metrics and Valuation
1 report, 1 independent
Updated Sep 28
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
A comparison of BioNTech and iBio shows differences in their financial profiles. BioNTech has 15.5% institutional ownership and 19.2% insider ownership, while iBio has 7.9% institutional ownership and 1.5% insider ownership. BioNTech is currently trading at a lower price-to-earnings ratio than iBio, and both companies have a beta of 1.29, indicating similar volatility relative to the S&P 500.
From dailypolitical.com
Why it matters
The comparison provides investors with metrics regarding the relative risk, profitability, and valuation of the two healthcare companies. BioNTech has a consensus target price of $1, according to analyst ratings.
From dailypolitical.com